• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Harvoni Shows Success Against Uncommon HCV Variants

Article

A treatment approved for the most common form of hepatitis C in the US was also highly effective in less widespread variants, researchers reported at the European Association for the Study of the Liver annual meeting.

A treatment approved for the most common form of hepatitis C (HCV) in the US was also highly effective in less widespread variants, researchers reported.

The 2-drug single-pill combination of sofosbuvir and ledipasvir (Harvoni) is indicated in the U.S. for genotype 1 HCV infection, noted Armand Abergel, MD, PhD, of the Hopital d'Estaing in Clermont-Ferrand, France, and colleagues.

But in an open-label study among patients with genotypes 4 and 5 disease, the combination yielded efficacy results that were similar to those seen in genotype 1, Dr Abergel reported in a plenary session at the European Association for the Study of the Liver annual meeting.

Read more at MedPage Today: http://bit.ly/1b6xuWA

Related Videos
Yuqian Liu, PharmD
Video 11 - "Social Burden and Goals of Therapy for Patients with Bronchiectasis"
Video 7 - "Harnessing Continuous Glucose Monitors for Type 1 Diabetes Management + Closing Words"
dr monica li
dr lawrence eichenfield
Video 14 - "Achieving Equitable Representation in Clinical Studies"
Video 13 - "Measuring Implicit Bias"
Dr Michael Morse, Duke University
Video 10 - "Bronchiectasis Exacerbation Management"
video 10  - "Developing Practical Solutions to Improve Cardiovascular Care"
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.